BT-11 is an orally active compound that binds to and activates the LANCL2 pathway. In preclinical studies, BT-11 has demonstrated potent effects on immune function in models of ulcerative colitis and Crohn’s disease. The compound increases anti-inflammatory cytokines, such as IL-10 and FOXP3 while decreasing pro-inflammatory markers, such as MCP1, TNF-alpha, and IFN-gamma in human immune cells. BT-11 is designed to avoid systemic exposure in the body and has the potential to avoid adverse side effects experienced with current therapies, supporting the potential for a safer treatment.
Landos is currently evaluating BT-11 in a Phase 2 study in ulcerative colitis and is planning to initiate a Phase 2 study in Crohn’s disease in 2020.